Update in sepsis guidelines: what is really new?

Rebecca Plevin, Rachael Callcut, Rebecca Plevin, Rachael Callcut

Abstract

Sepsis remains a highly lethal entity resulting in more than 200 000 deaths in the USA each year. The in-hospital mortality approaches 30% despite advances in critical care during the last several decades. The direct health care costs in the USA exceed $24 billion dollars annually and continue to escalate each year especially as the population ages. The Surviving Sepsis Campaign published their initial clinical practice guidelines for the management of severe sepsis and septic shock in 2004. Updated versions were published in 2008, 2012 and most recently in 2016 following the convening of the Third International Consensus Definitions Task Force. This task force was convened by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine to address prior criticisms of the multiple definitions used clinically for sepsis-related illnesses. In the 2016 guidelines, sepsis is redefined by the taskforce as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In addition to using the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score to more rapidly identify patients with sepsis, the task force also proposed a novel scoring system to rapidly screen for patients outside the ICU who are at risk of developing sepsis: the 'quickSOFA' (qSOFA) score. To date, the largest reductions in mortality have been associated with early identification of sepsis, initiation of a 3-hour care bundle and rapid administration of broad-spectrum antibiotics. The lack of progress in mortality reduction in sepsis treatment despite extraordinary investment of research resources underscores the variability in patients with sepsis. No single solution is likely to be universally beneficial, and sepsis continues to be an entity that should receive high priority for the development of precision health approaches for treatment.

Keywords: sepsis; septic shock.

Conflict of interest statement

Competing interests: None declared.

References

    1. De Backer D, Dorman T. Surviving sepsis guidelines: a continuous move toward better care of patients with sepsis. JAMA 2017;317:807–8.
    1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167–74.
    1. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M,et al. . Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762–74.
    1. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med 2014;42:625–31.
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840–51.
    1. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet 2010;376:1339–46.
    1. Epstein L, Dantes R, Magill S, Fiore A. Varying Estimates of sepsis mortality using death certificates and administrative codes--United States, 1999-2014. MMWR Morb Mortal Wkly Rep 2016;65:342–5.
    1. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308–16.
    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS,et al. . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–10.
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R,et al. . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.
    1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Reinhart K,et al. . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637.
    1. Antonelli M, DeBacker D, Dorman T. Surviving Sepsis campaign responds to Sepsis-3. (accessed 1 Mar 2016).
    1. Rivers E, Nguyen B, Havstad S. Early Goal-Directed therapy Collaborative Group. early goal-directed therapy in the treatment of severe Sepsis and septic shock. N Engl J Med 2001;345:1368–77.
    1. Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R, Canter RR, Coats TJ, Delaney A, Gimbel E, Grieve RD,et al. . Early, Goal-Directed therapy for septic shock - A Patient-Level Meta-Analysis. N Engl J Med 2017;376:2223–34.
    1. Yu H, Chi D, Wang S, Liu B. Effect of early goal-directed therapy on mortality in patients with severe sepsis or septic shock: a meta-analysis of randomised controlled trials. BMJ Open 2016;6:e008330
    1. Society of Critical Care Medicine (SCCM). Updated Bundles in response to New evidence. (accessed at Apr 2015).
    1. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, Lemeshow S, Osborn T, Terry KM, Levy MM,et al. . Time to treatment and mortality during Mandated Emergency Care for Sepsis. N Engl J Med 2017;376:2235–44.
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME,et al. . Surviving Sepsis campaign: international guidelines for management of Sepsis and Septic shock: 2016. Intensive Care Med 2017;43:304–77.
    1. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, et al. . Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301–11.
    1. Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA,et al. . Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014;371:1496–506.
    1. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F,et al. . A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683–93.
    1. Howell MD, Davis AM. Management of sepsis and septic shock. JAMA 2017;317:847–8.
    1. Dellinger RP, Schorr CA, Levy MM. A users’ guide to the 2016 surviving sepsis guidelines. Crit Care Med 2017;45:381–5.
    1. Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Runyon MS, Self WH, Courtney DM, Nowak RM, Ebmeyer S,et al. . Serial Procalcitonin predicts mortality in Severe Sepsis patients: results from the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med 2017;45:781–9.
    1. Yende S, Thompson BT. Evaluating glucocorticoids for sepsis: time to change course. JAMA 2016;316:1769–71.
    1. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Aneman A, Vang ML, Winding R,et al. . Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381–91.
    1. Rygård SL, Holst LB, Wetterslev J, Johansson PI, Perner A. Higher vs. lower haemoglobin threshold for transfusion in septic shock: subgroup analyses of the TRISS trial. Acta Anaesthesiol Scand 2017;61:166–75.
    1. Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, Koami H, Beppu S, Katayama Y, Itoh M,et al. . Effect of dexmedetomidine on mortality and Ventilator-Free days in patients requiring mechanical ventilation with Sepsis: a randomized clinical trial. JAMA 2017;317:1321–8.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit